The pharma major announced that its wholly-owned subsidiary in United Kingdom, Cipla (EU) will invest an additional EUR 3 million in Ethris GmbH, a global leader in delivering mRNAs directly to the respiratory system.
| Subscribe To Our Free Newsletter |
